Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.24750
Abstract: Key Points Question What are the epidemiologic trends of and prognostic factors for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients in the US? Findings In this cohort study of 43 751 patients with GEP-NETs, most cases occurred… read more here.
Keywords: neuroendocrine tumors; associated overall; gastroenteropancreatic neuroendocrine; overall survival ... See more keywords
STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gastrointestinal Surgery"
DOI: 10.1007/s11605-019-04261-6
Abstract: Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are highly vascular neoplasms treated similarly, irrespective of tumor location. The expression of pro-angiogenic factors (STAT3, VEGF, and HIF-1α) and their association with adverse pathologic factors and disease recurrence following… read more here.
Keywords: high stat3; neuroendocrine tumors; expression; gastroenteropancreatic neuroendocrine ... See more keywords
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-021-01029-7
Abstract: The purpose of our review is to explore global epidemiologic trends of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Specifically, we sought to examine whether there are differences in incidence, prevalence, distribution (by primary tumor site, tumor… read more here.
Keywords: incidence; incidence prevalence; epidemiology; gep nets ... See more keywords
Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-98588-7
Abstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present unique challenges due to their heterogeneity and limited treatment options. Oncolytic virotherapy has emerged as a promising therapeutic for other NETs and thus, we sought to investigate the potential of… read more here.
Keywords: oncolytic herpes; gastroenteropancreatic neuroendocrine; gep nets; herpes simplex ... See more keywords
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2207829
Abstract: ABSTRACT Introduction Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a complex and heterogenous family of solid malignancies that originate from neuroendocrine tissue in the gastrointestinal tract or pancreas. Most patients diagnosed with GEP-NETs present with advanced or… read more here.
Keywords: gep nets; qol; patients advanced; life ... See more keywords
Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13260
Abstract: Refined risk stratification for gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) has the potential to improve comparisons of study populations across clinical trials and facilitate drug development. Tumor growth rate (TGR) is a radiological metric with demonstrated prognostic… read more here.
Keywords: tumor growth; gep nets; growth rate; neuroendocrine tumors ... See more keywords
Fragility fractures in well‐differentiated gastroenteropancreatic neuroendocrine tumors: Results from a multicentered retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.70053
Abstract: Patients with gastroenteropancreatic–neuroendocrine tumors (GEP‐NETs) may present skeletal fragility that might be related to multiple factors, including bone metastases, vitamin D deficiency, hormone secretion, and disease treatments. This study examines the prevalence and determinants of… read more here.
Keywords: gastroenteropancreatic neuroendocrine; gep nets; fragility; neuroendocrine tumors ... See more keywords
Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211018047
Abstract: Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent the most common subtype of NETs. The incidence of all NETs, and specifically GEP NETs, has risen exponentially over the last three decades. Only within the past several years… read more here.
Keywords: 177lu dotatate; well differentiated; neuroendocrine tumors; receptor ... See more keywords
Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Diabetes and Endocrinology"
DOI: 10.1186/s40842-018-0066-3
Abstract: BackgroundNeuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system. More than half originate from endocrine cells of the gastrointestinal… read more here.
Keywords: treatment; current treatment; treatment options; treatment strategies ... See more keywords
Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.4020
Abstract: 4020 Background: 212Pb-DOTAMTATE is a Targeted Alpha Therapy (TAT) in clinical development for subjects with SSTR+ neuroendocrine tumors. A phase I dose-escalation study has already been completed (Delpassand et al. J Nucl Med 2022). TAT… read more here.
Keywords: 212pb dotamtate; therapy; gep nets; response ... See more keywords
c-MET Inhibition: Novel Treatment for Sporadic and MEN1-associated GEP NET.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of molecular endocrinology"
DOI: 10.1530/jme-20-0020
Abstract: Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) comprise a heterogenous and diverse group of neoplasms arising from a common neuroendocrine cell origin. The majority of these tumors occur sporadically while ~20% manifest within the context of hereditary… read more here.
Keywords: met inhibition; men1 associated; sporadic men1; men1 ... See more keywords